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CytokinesAbstract Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by synovial
inﬂammation triggered by inﬁltrating CD4 lymphocytes. The positioning and activation of lympho-
cyte in inﬂamed synovial tissues are dependent on a number of factors including their chemokine
receptor expression proﬁle. We aimed to investigate which chemokine receptors pattern correlate
with serum cytokine levels and with disease activity. Forty patients with RA (34 female and 6 male)
with age range from 21 to 68 years were included. Twenty healthy volunteers (16 female and 4 male)
with matched age (range 21–48 years) were served as healthy controls (HCs). Expression of chemo-
kine receptors (CCR5, CX3CR1 and CCR7) together with the apoptosis-related marker (CD95)
was analyzed using three-color ﬂow cytometry analysis after gating on CD4+ peripheral blood lym-
phocytes. Plasma levels of IL-6, IL-10, IL-12 and TNF-a cytokines were measured in all par-
ticipants using ELISA. Disease activity score (DAS28-CRP) system was assessed and active
disease was deﬁned as DAS28 P3.2. Twenty-ﬁve (62.4%) patients were classiﬁed as active RA
(ARA) and 15 (37.5%) patients with inactive RA (IRA). Percentages of CD4+ lymphocytes
454 A.M. Aldahlawi et al.expressing CD95 with either of CCR7 or CCR5 were signiﬁcantly higher in ARA compared to IRA
and HCs groups, while the expression of CX3CR1 on T-cells was found signiﬁcantly lower in both
CD95 and CD95+ T-cells in RA groups than HC. Percentages of CD4+CD95+CCR7+ cells
correlated positively with IL-6 (r= 0.390). Whereas CD4+CD95+CX3CR1+ were negatively
correlated with TNF-a (r= 0.261). Correlation of CD4+CD95+CCR7+ T cell subset with dis-
ease activity and inﬂammatory cytokines suggests a role for this cell subset in the pathogenesis
of RA. Further investigation will be required to fully characterize this cell subset and its role in
disease progression.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Rheumatoid arthritis (RA) is a chronic systemic autoimmune
disease characterized by persistent inﬂammation affecting the
musculoskeletal system that results in joints deformation and
severe pain. The precise pathogenesis of RA has not been
completely elucidated, but CD4+ T cells are thought to play
a crucial role, as it stimulate proliferation and differentiation
of B-lymphocytes (Hovdenes, 1989) and participate in the
induction and propagation of inﬂammatory responses by
secreting pro-inﬂammatory cytokines, growth factors, and
interferons (Chen et al., 2004; Perng et al., 2014).
Trafﬁcking of CD4+ T cells, and consequently their
inﬂammatory mediators, into the synovial ﬂuid contribute to
initiation, propagation, and maintenance of chronic inﬂamma-
tion of synoviocytes (Berner et al., 2000; Bradﬁeld et al., 2003).
The migration of CD4+ T cells as well as other immune cells to
lymphoid or rheumatoid synovium is dependent on several fac-
tors including their chemokine receptors expression proﬁle
(Szekanecz et al., 2010). The chemokine receptor (CCR)5 has
been reported to play key roles in the intra-articular recruit-
ment of peripheral blood mononuclear cells (Portales et al.,
2009). CCR5 upregulation was found associated with tissue
and joint destruction and increased levels of CCR5 ligands
(RANTES, MIP-1a, and MIP-1b) in the synovial ﬂuid
(Fleishaker et al., 2012). CX3CR1 is a chemokine receptor that
binds to the proinﬂammatory chemokine fractalkine (FKN or
CX3CL1). CX3CR1 has been shown to be important in
inﬂammatory arthritis responses largely due to effects on cellu-
lar migration (Nanki et al., 2002; Tarrant et al., 2012). CCR7
was found to be important in lymphocytes homing to joints in
response to the cognate ligands CCL19 and CCL21. In addi-
tion, CCR7 ligands have been detected in endothelial cells
and in the perivascular inﬁltrate in RA synovium, suggesting
their potential involvement in lymphoid neogenesis that occurs
in inﬂamed synovial tissue (Pickens et al., 2012).
In addition to their role in lymphocytes trafﬁcking,
chemokine receptors were found crucial to the regulation of
gene expression on target cells and help to control cell
proliferation and apoptosis (Muller et al., 2002). Apoptosis
resistance or longevity of CD4+ T cells is linked to excessive
inﬁltration of lymphocytes which is considered to exacerbate
and maintain synovitis in RA (Moodley et al., 2011; Gullick
et al., 2013). CD95 is a membrane receptor belonging to the
tumor necrosis factor (TNF) receptor superfamily that
plays a pivotal role in maintaining lymphocytes homeostasis
and tolerance by mediating apoptosis in activated maturelymphocytes (Dudley et al., 1999; Paulsen et al., 2011).
Additionally CD95 was reported to participate in non-
apoptotic processes including cellular activation, differen-
tiation and induction of inﬂammation (Peter et al., 2007;
Paulsen and Janssen, 2011; Li et al., 2014). Mutation in
CD95 was found associated with autoimmune disease in lpr
mice and in humans (Cui et al., 1996; Vaishnaw et al., 1999).
Therefore, we aimed to investigate whether the expression
pattern of chemokine receptors and the apoptosis-related
receptor CD95 on CD4+ T-cells correlates with inﬂammatory
cytokines and disease activity index in RA patients.2. Material and methods
2.1. Patients
This study was approved by the Ethics Committee of King
Abdulaziz University Hospital. The study included patients
from the rheumatology outpatient clinic at the King Abdulaziz
University Hospital. Forty patients with RA (34 women and 6
men) with age ranged between 21 and 68 years who fulﬁlled the
American College of Rheumatology (ACR) 1987 criteria for
the diagnosis of RA (Arnett et al., 1988) were included. Twen-
ty healthy volunteers (16 female and 4 male) with matched age
(range 21–48 years) who have no involvement for other
autoimmune disease were included as healthy control (HC)
group. RA patients had disease duration between 1 and
240 months. Group of patients received combined therapy of
methotrexate and prednisolone (n= 19; 7.5 mg–5.5 mg/week,
5 mg–10 mg/day), while rest of them (n= 21) have not
received any treatment for RA.
Disease activity was determined using DAS28-CRP accord-
ing to previously established methods (Prevoo et al., 1995).
According to DAS-28, 25 (62.5%) patients were classiﬁed with
active RA (ARA) and 15 (37.5%) patients with inactive RA
(IRA). The Clinical and laboratory features of subjects in
ARA, IRA and HCs groups are presented in Table 1.
2.2. Blood samples
Ten ml blood sample was drawn from each RA and HC sub-
jects into a BD vacutainer tube containing ethylene diamine
tetra-acetic acid (EDTA) anticoagulant. Plasma samples were
separated after centrifugation at 1500 rpm for 10 min, and
then it was stored at 80 C till further analysis. Fresh whole
blood samples were used for ﬂow cytometric analysis.
Table 1 Clinical and biochemical analyses of RA patients and healthy controls.
Groups Active RA (No. = 25) Inactive RA (No. = 15) HC (No. = 20) ANOVA P-value
Age (years) 43.8 ± 12.0 43.1 ± 13.8 35.7 ± 7.1 –
Disease duration (months) 76.4 ± 72.6 91.6 ± 109.7 – 0.638
DAS-28 3.96 ± 0.59 2.7 ± 0.27 – 0.002
ESR (mm/h) 30.8 ± 23.09 21.1 ± 16.33 12.23 ± 5.88 0.002
CRP (mg/l) 26.0 ± 39.94 7.61 ± 5.11 4.87 ± 3.4 0.017
Anti-CCP (+ve > 50 units/ml) 16/25 (64%) 7/15 (47%) 0/20 (0%) 0.009
RF (+ve > 20 units/ml) 11/25 (44%) 9/15 (60%) 0/20 (0%) 0.045
IL-6 (pg/ml) 19.79 ± 5.45 15.81 ± 5.1 13.8 ± 5.49 0.034
IL-10 (pg/ml) 11.78 ± 3.68 11.6 ± 2.27 10.86 ± 3.78 0.881
IL-12 (pg/ml) 13.1 ± 3.92 13.39 ± 1.22 14.53 ± 2.20 0.793
TNF-a (pg/ml) 17.67 ± 3.17 16.01 ± 4.06 12.17 ± 3.51 0.038
Values are expressed as mean ± SD.
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Erythrocyte sedimentation rate (ESR) was measured using the
Westergren technique, C-reactive protein (CRP) was measured
by nephelometry and CBC was counted using automated
blood counter. Anti-CCP concentrations were determined
using commercial kits purchased from IMTEC, Immunodiag-
nostica GmbH. Samples with concentrations >25 units/ml
were considered positive (Karimifar et al., 2012).
2.4. Flow cytometric analysis
Three color ﬂow cytometry ﬂuorescence staining was used for
the analysis of lymphocytes. The blood of patients and con-
trols was stained with PerCP conjugated anti-CD4, PE conju-
gated CCR7, CCR5 or CX3CR1 and ﬂuorescein
isothiocyanate (FITC) conjugated CD95. These antibodies
were purchased from R&D Systems (Minneapolis MN,
USA). Antibodies or the corresponding isotopic control
(IgG1, IgG2A-PE and IgG2A-Percp), were added at the con-
centration of 1 lg/100 lL of whole blood samples and incubat-
ed for 30 min, at 4 C at the dark. Then, 3 ml of freshly
prepared RBC lysis (1·) buffer was added, samples were mixed
promptly and thoroughly to ensure complete erythrocyte lysis.
Then, samples were incubated for 10 min at room temperature.
Samples were centrifuged at 1500 rpm for 7 min and the super-
natant was discarded. This step was repeated if the RBC still
not lysis. Cells were resuspended in 400 ll of cold PBS. The
immunophenotype was assessed by triple-color cytometry. Cell
ﬂuorescence was measured using a ﬂow cytometer (FACScal-
ibur, Becton–Dickinson, San Jose, CA, USA) and analyzed
with green (FL1), orange (FL2) or red (FL3) standard emis-
sion ﬁlters. From each sample 10,000 events were acquired.
Based on side scattered (SC) versus forward scattered (FS) dis-
tribution of lymphocytes were gated from the whole PBMC
population (Baumgarth and Roederer, 2000).
2.5. Detection of plasma cytokines
Stored plasma samples at 80 C were used to determine the
concentrations of IL-6, IL-10, IL-12 and TNF-a using
enzyme-linked immunosorbent assay (ELISA), following the
manufacturer’s instructions (all ELISA kits from BioLegend,Inc., San Diego, CA, USA). All samples were measured in
duplicate.
2.6. Statistical analysis
Values are expressed as mean ± SD or median (range) in the
tables and ﬁgures. Data were analyzed using SPSS (version
16.0, SPSS Inc., USA). Data were analyzed by one way
ANOVAs, Bonferroni, Pearson correlation (r) and T-test. A
P value < 0.05 was considered signiﬁcant.3. Results
Table 1 demonstrates the differences in clinical and
biochemical markers of patient groups and healthy controls.
No signiﬁcant difference was detected in age among RA
patients and healthy controls. Additionally, no signiﬁcant dif-
ference was detected in disease duration between ARA and
IRA patients. However, there were signiﬁcant differences
between studied groups in DAS-28 (P= 0.002), ESR
(P= 0.002), CRP (P= 0.017), Anti-CCP (P= 0.009) and
RF (P= 0.045). The plasma concentrations of IL-6, IL-10,
IL-12 and TNF-a were signiﬁcantly increased in patients with
active RA and inactive RA compared to that of healthy sub-
jects (Table 1). The correlations between the inﬂammatory
parameters and cytokines and between the parameters and
chemokines receptors are summarized in Table 2.
Fig. 1 shows the mean percentages of CD4+ cells express-
ing CCR5, CCR7, CX3CR1 and CD95 in patients with
ARA, IRA and HCs. Mean percentage of CD4+CCR5+
CD95+ and CD4+CCR5+CD95 T cells was signiﬁcantly
higher in ARA comparing to IRA patients and HCs (both at
P< 0.05). On the other hand, there was no signiﬁcant differ-
ence in CD4+CCR5+CD95+ and CD4+CCR5+CD95 T
cells between IRA and HCs (Fig. 1A). For CCR7 expression
on CD4+ cells (Fig. 1B), CCR7+CD95+CD4+ T-lympho-
cytes signiﬁcantly increased in ARA compared with IRA
(P= 0.05) and HCs (P= 0.01). In addition, CCR7+CD95+
CD4+ T cells were signiﬁcantly higher in IRA patients than
HCs (P= 0.05). Whereas, no signiﬁcant differences were
detected between the three groups as regard CCR7+CD95
CD4+ T cells. The percentages of cells expressing CX3CR1+
CD4+CD95+ and CX3CR1+CD4+CD95 were signiﬁcantly
Table 2 Correlations of T cell subsets with clinical and biochemical parameters.
CD4+CCR5+ CD4+CCR7+ CD4+CX3CR1+
CD95 CD95+ CD95 CD95+ CD95 CD95+
DAS28 0.102 0.004 0.079 0.371** 0.06 0.197
Anti-CCP 0.107 0.075 0.168 0.212 0.014 0.079
ESR 0.019 0.043 0.001 0.192 0.142 0.056
RF 0.106 0.026 0.027 0.363** 0.122 0.04
CRP 0.146 0.022 0.206 0.052 0.137 0.094
IL-6 0.013 0.022 0.038 0.331* 0.078 0.114
IL-10 0.009 0.045 0.064 0.107 0.297* 0.057
IL-12 0.094 0.056 0.063 0.149 0.031 0.176
TNF-a 0.098 0.066 0.095 0.149 0.065 0.261*
* Correlation is signiﬁcant at the 0.05 level (2-tailed).
** Correlation is signiﬁcant at the 0.01 level (2-tailed).
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P< 0.05). On the other hand, there was no signiﬁcant
difference in CD4+ CX3CR1+CD95+ and CD4+
CX3CR1+CD95 T cells between ARA and IRA (Fig. 1C).
4. Discussion
CD4+ T cells play a crucial role in inﬂammatory responses
affecting joints and adjacent tissues via the production of dis-
tinctive sets of inﬂammatory cytokines (Tak et al., 1995; Nanki
and Lipsky, 2000). Recent data suggest that CD95 not only
induces apoptosis, but also acts as an activator marker of
CD4+ T cells due to its role in regulating the activation of
transcription factors and cell-cycle regulators for the induction
of proliferation and cytokine production (Paulsen et al., 2011).
Additionally CD95 has been found to promote proliferation of
rheumatoid arthritis ﬁbroblast-like synoviocytes and induce
inﬂammation through a mechanism involving the activation
of PI3K/Akt signaling pathway (Li et al., 2014).
These data encouraged us to investigate whether RA dis-
ease activity and inﬂammatory cytokines are associated with
certain proﬁle of CD95 and chemokine receptors expression
on CD4+ T cells. Results showed that the dual expression of
CD95 with CCR7 on CD4+ T cells was able to differentiate
between active, inactive RA patients and healthy control
(Fig. 1A). Whereas CD95+CCR5+ and CD95+CX3CR1+
CD4+ T-cells failed to differentiate between the three studied
groups signiﬁcantly (Fig. 1B and C).
CCR7 was reported to be expressed only by naive and
central memory T cells that control their transmigration into
lymphoid tissues in response to the cognate ligands CCL19
and CCL2 (Forster et al., 2008). Furthermore, CCR7 was
found critical for the generation of an adaptive T-cell response
(Toka et al., 2003).
Our ﬁnding that CD4+CD95+ T-lymphocytes express
higher amount of CCR7 in RA compared with controls; may
suggest that there is an increase in homing of this activated
(CD95+) T cell subsets to either secondary lymphoid tissue
or node-like synovium microstructure and hence contributing
to its inﬂammatory environment by secreting inﬂammatory
cytokines.
Additionally, the increased CD95+CCR7+CD4+ T cells
probably will result in increased apoptotic bodies and over pre-
sentation of lymphocytes’ remnants that might break immunetolerance, resulting in the autoimmune phenomena or boost an
already existing autoimmune response as previously reported
by Lorenz et al. (2000). In line with these data our results
showed signiﬁcant positive correlations between CD95+
CCR7+CD4+ T cells with DAS28 and RF, whereas CD95
CCR7+CD4+ T cell subset did not correlate with these
parameters. This ﬁnding conﬁrms that CD95+CCR7+CD4+
T cell subset may contribute in the pathogenesis of RA.
CD95+CCR7+CD4+ T cell subset was also found strongly
correlated with IL-6. IL-6 is considered a key mediator in the
inﬂammatory process of RA and has been found at elevated
levels in the serum and synovial tissue (Smolen et al., 2014).
Therefore we suggest that the positive relationships between
CD95+CCR7+CD4+ T cells with IL-6 may interpret their
positive correlations with DAS28 and RF.
CX3CR1 and its ligand fractalkine (FKN) are strongly
expressed in the chronically inﬂamed synovial tissue of patients
with RA (Umehara et al., 2006). CX3CR1 is expressed on
leukocytes and mediate not only chemotaxis, but also their ﬁrm
adhesion to FKN-expressing endothelial cells even in the
absence of substrates for other adhesion molecules (Fong
et al., 1998). In our study we found a signiﬁcant decrease in
both subsets of CX3CR1+CD4+ T cells compared with that
of healthy control. This ﬁnding suggests that CX3CR1+ cells
have migrated from peripheral circulation to inﬂamed tissues
making their percentages decreased in RA patients than
healthy controls. This is also in agreement with Nanki et al.
(2002) who found that the interactions of CX3CL1 and
CX3CR1 might contribute to the accumulation of CX3CR1+
T cells expressing type 1 cytokines and possessing cytotoxic
granules in RA synovium. This conclusion is supported by
the ﬁnding of negative correlations of TNF-a with peripheral
blood CD4 lymphocytes expressing CX3CR1. TNF-a
particularly plays a pivotal role in the pathogenesis of RA. It
is present at biologically signiﬁcant levels in RA synovial tissue
and ﬂuid. Moreover, the TNF-a level seem to parallel the sever-
ity of both inﬂammation and bone erosion (Matsuno et al.,
2002). Accumulating evidence suggests that not only soluble
TNF-a, but also its precursor form transmembrane TNF-a
involved in the inﬂammatory response (Nakashima et al., 2010).
CCR5 is a key chemokine receptor that is highly expressed
on CD4+ T cells. It binds to three different chemokines CCL3
(MIP-alpha), CCL4 (MIP-beta), and CCL5 (RANTES).
Ample evidence suggested that the interaction between
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Figure 1 (A–C) The mean percentages of CD4+ cells expressing
CCR5, CCR7, CX3CR1 and Fas in the studied groups. Values are
expressed as mean percent ± SD. *Signiﬁcant by ANOVA at
P< 0.05. aSigniﬁcant at P< 0.05 versus active RA, bSigniﬁcant
at P< 0.05 versus inactive RA.
Chemokine receptors expression on peripheral CD4-lymphocytes 457CCR5 and its ligands is essential not only for attracting these
CCR5+ T cells but also substantial for transuding co-signals
for their activation (Wu et al., 2008). In addition, CCR5 has
been reported to directly regulate T-cell function in autoim-
mune diseases, including MS and RA (Solomon et al., 2010).
In our results there was a signiﬁcant increase in the percent-
age of CCR5+CD4+ T cells in the ARA in comparison with
IRA and HCs groups. However the mean percentage of
CCR5+CD4 T cells did not correlate with any of the clinical,
inﬂammatory or the cytokine markers. This result is in accor-
dance with the previous study by Sapir et al. (2010) who found
that production of inﬂammatory cytokines TNF-alpha, IL-17,
and IFN-gamma, are CCR5 independent and therefore likely
to be mediated by the other receptors. These observations were
also supported at the molecular level by the ﬁnding that CCR5gene polymorphism do not play a major role in conferring
genetic risk for, and/or protection against other autoimmune
disease (Gambelunghe et al., 2004).
In conclusion, our data suggest that the percentage of
CD4+ T-cells coexpressing CD95 and CCR7 associate with
disease activity and inﬂammation, and may serve as valuable
index in monitoring the disease activity and the efﬁcacy of
the treatment. In addition, these data suggest that targeting
this cell subset for therapeutic intervention could potentially
lead to lower inﬂammation and disease progression in RA.
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